Servier, in Collaboration with Allogene Therapeutics, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T Therapy
28/01/2019
Servier and Neurochlore launch phase 3 studies in Europe to evaluate bumetanide in children suffering from Autism Spectrum Disorders
23/01/2019
WeHealth by Servier launches Cardioskin, an ambulatory digital medical device that records cardiac activity in real time
16/01/2019
WeHealth by Servier and PathMaker Neurosystems form partnership for a Breakthrough Non-Invasive Neuromodulation Device for the Treatment of Spasticity
09/01/2019
Servier joins Embleema's Blockchain Health Consortium to launch a pilot project for Blockchain
04/12/2018
Servier and Allogene Therapeutics present pooled data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia
04/12/2018
WeHealth by Servier and MobioSense form a partnership to develop digital portable heart attack detection test
26/11/2018
Servier backs an American startup at LabCentral in the field of mitochondrial health for neurodegenerative and rare diseases
14/11/2018
Servier joins Patient-Focused Medicines Development (PFMD) Collective Platform
25/10/2018
Servier, in the top 5 companies favoured by students and young graduates
18/10/2018
Servier and Poietis announce scientific partnership in 4D bioprinting of liver tissues
19/09/2018
Servier backs the research project of an American startup in the field of oncology
26/04/2018
WeHealth by Servier and UCSF form partnership to identify most promising e-health startups
12/04/2018
Servier and Scandicure enter into agreement to conduct research in the field of metabolic diseases
03/04/2018
GeNeuro and Servier announce successful 12-month results in neuroprotection for Phase 2b CHANGE-MS Study with GNbAC1 in Multiple Sclerosis
26/03/2018
WeHealth by Servier and DEEPLINK MEDICAL sign a partnership to develop a new e-health solution in the field of oncology
13/03/2018
Servier and ImmunoQure AG enter into strategic partnership for the development of an Interferon - αhuman autoantibody
06/02/2018
Servier and Treventis begin strategic research partnership in neurodegenerative disease
04/01/2018
Preliminary Data from Servier and Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials
13/12/2017
Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting
01/11/2017
Servier and GeNeuro Announce Promising post hoc Analyses of Six-Month Data from CHANGE-MS Phase 2b Study at MSParis2017
28/10/2017
Servier establishes strategic research alliance with Harvard University
19/10/2017
Servier opts for Saclay as its future Research Centre
04/10/2017
Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T
29/06/2017
Servier is the first French pharmaceutical company to partner with Plug and Play Health & Wellness
27/06/2017
Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
09/03/2017
Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
06/01/2017
New Compound shows promise in treating multiple human cancers
20/10/2016
Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
11/07/2016
Patients with Advanced Metastatic Colorectal Cancer in Europe Now Have a New Treatment Option as LONSURF® (trifluridine/tipiracil) Receives EU Approval
27/04/2016
ISHR-ES – Servier Research Fellowship 2016 awarded to Dr Hector Cabrera-Fuentes
22/04/2016
40th year of operations in Brazil
06/04/2016
Servier Receives Positive CHMP Opinion for LONSURF® (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
26/02/2016
Spectrum Pharmaceuticals Signs a Strategic Partnership with Servier Canada
11/01/2016
Servier announces expansion of collaboration for the development and commercialization of anticancer drug candidates targeting apoptosis
07/12/2015
Horizon Discovery Group plc In-licenses Oncology Programme from Servier and Enters Option Agreement
07/10/2015
Servier offers its expertise in industrial R&D, chemical synthesis and pharmaceutical manufacturing to partners.
05/10/2015
Cellectis Reaches Milestone in Servier Collaboration
09/07/2015
VECT-HORUS announces the signing of a scientific collaboration agreement with SERVIER
17/06/2015
Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe
15/06/2015
FDA approves ivabradine for patients with chronic heart failure
16/04/2015
Servier, 8th European investor in the pharmaceutical sector
15/12/2014
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of Multiple Sclerosis
02/12/2014
Intarcia and Servier sign ex-U.S. partnership for ITCA 650 in diabetes; Intarcia retains independence & full control of the U.S. & Japan
12/11/2014
Servier new research partnership with the Walter and Eliza Hall Institute to target Achilles’ heel of many cancers
02/10/2014
Servier and CTI Biopharma announce exclusive license and collaboration agreement to develop and commercialize PIXUVRI®
17/09/2014
Xention and Servier commence first phase 2 study of XEN-D0103/S66913 in atrial fibrillation
01/09/2014
Servier Research Grant in Hypertension
27/08/2014
Galapagos receives milestone in osteoarthritis alliance with Servier
06/08/2014
Vernalis and Servier achieve two Research Milestones in their Oncology Collaborations
06/08/2014
Servier announces that its partner MacroGenics has initiated the first Phase 1 Study for MGD006/ S80880 for the Treatment of Acute Myeloid Leukemia
18/07/2014
Servier launches Cardiological, a mobile medical application to understand cardiovascular diseases
03/07/2014
Servier and miRagen Extend Collaboration for the Research, Development and Commercialization of microRNA-targeting Drugs for Cardiovascular Disease
23/06/2014
Vernalis and Servier achieve Research Milestone as BCL-2 inhibitor drug candidate enters Phase I
19/06/2014
The winner of the 2014 Jean Delay Prize is Professor Mitsumoto Sato, from Japan
07/05/2014
